Developing new mRNA vaccines to improve melanoma treatment
Official title: Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
Funded at University of Michigan at Ann Arbor · NIH-10990224 · Data updated 2026-11-12
This study is testing a new type of small vaccine designed to boost the effectiveness of current melanoma treatments, helping your immune system fight the cancer better and longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $577,293 |
| NIH project number | 1R01CA286122-01A1 |
| Project ID | NIH-10990224 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are melanoma patients who have not responded to current immune checkpoint blockade therapies.
✕Less likely to help
Patients with early-stage melanoma or those who have not yet undergone any form of immunotherapy may not benefit from this research.
What this research studies
This research focuses on creating innovative small circular mRNA vaccines aimed at enhancing the effectiveness of existing melanoma treatments, particularly immune checkpoint blockade therapy. By addressing the limitations of conventional vaccines, such as stability and immune response, the study aims to develop a more effective immunotherapy option. The approach involves using highly stable, modification-free multivalent small circular mRNA that can efficiently stimulate the immune system to target melanoma cells. Patients may benefit from a more robust and lasting immune response against their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective melanoma treatments that improve patient outcomes and survival rates.
How similar studies have gone: Previous research has shown promise in using mRNA vaccines for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Zhu, Guizhi — University of Michigan at Ann Arbor
- Study coordinator: Zhu, Guizhi
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
New approach to overcome resistance to immunotherapy in melanoma
A new strategy targets a key pathway in melanoma to boost the effectiveness of immune-based therapies for patients whose cancer resists treatment.
-
Multivalent circular mRNA vaccines for melanoma immunotherapy
A cancer vaccine approach using tiny circular mRNA vaccines aimed at boosting immune responses against melanoma in combination with existing immunotherapies.
-
Lymph Node–Targeted Co-delivery for Melanoma Immunotherapy
Aimed at improving melanoma treatment, this project tests a targeted vaccine approach that helps the body’s immune system better attack skin cancer.
-
Multifunctional nanoparticles to boost melanoma immunotherapy
A new nanoparticle approach using ultrasound-triggered systems aims to make melanoma immunotherapy work better for patients who don’t respond well to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.